Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a80cbaaeee718664126e579cf4e41c2 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
filingDate |
2015-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b43a3921f2221170da78aba2ff729a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0dbcc7f4b4d5333f54cf6c92b6eee7e |
publicationDate |
2015-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2015180639-A |
titleOfInvention |
Treatment method based on polymorphism of KCNQ1 gene |
abstract |
Compound QT interval in a method of treating with a compound capable of prolonging the electrocardiogram QT interval (time from the beginning of the Q wave to the end of the T wave) in a patient receiving a psychotropic drug Of methods to predict the effects on patients and determine the dose of psychotropic drugs to patients. A patient further comprising determining at least a portion of a KCNQ1 gene sequence associated with the patient's voltage-gated potassium channel and determining at least a portion of the patient's cytochrome P450 2D6 (CYP2D6) gene sequence. Administering to the patient an amount of a psychotropic drug based on the KCNQ1 gene sequence of the patient. [Selection figure] None |
priorityDate |
2009-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |